Product Information
OTREXUP 17.5 MG/0.4 ML AUTOINJ is a brand product labeled by Antares Pharma, Inc., priced at $476.9597 per ML under NDC 54436001704. Its NADAC has been published 83 times since Apr 17, 2024.
The High Outlier badge above means this manufacturer's average price in the methotrexate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
17.5 mg/.4mL
Manufacturer
Antares Pharma, Inc.NDC
54436001704
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Last Updated
4/1/2025
Active Ingredients
METHOTREXATEApproval Type
New Drug (NDA)
FDA Application
NDA204824On Market Since
10/11/2013
Pharmacological Classes
Price Statistics
The NADAC for OTREXUP 17.5 MG/0.4 ML AUTOINJ has been published 83 times since Apr 17, 2024, and over the history we have for it it has risen 2.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $476.9597 per ML |
|---|---|
| All-time high | $476.9597 (Nov 12, 2025) |
| All-time low | $463.5177 (Apr 17, 2024) |
| 52-week high | $476.9597 |
| 52-week low | $476.9597 |
| Median price | $463.5177 |
| Average price | $468.7002 |
| Largest weekly change | +2.9% (Apr 9, 2025) |
| Weeks tracked | 83 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 14% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of OTREXUP 17.5 MG/0.4 ML AUTOINJ?
The current National Average Drug Acquisition Cost (NADAC) for OTREXUP 17.5 MG/0.4 ML AUTOINJ, manufactured by Antares Pharma, Inc., is $476.9597 per ML (NDC 54436001704), effective Nov 12, 2025.
How has the price of OTREXUP 17.5 MG/0.4 ML AUTOINJ changed over time?
Over the history we have for it, the NADAC for OTREXUP 17.5 MG/0.4 ML AUTOINJ has risen 2.9%. It has been tracked across 83 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for OTREXUP 17.5 MG/0.4 ML AUTOINJ?
Since Apr 17, 2024, the NADAC for OTREXUP 17.5 MG/0.4 ML AUTOINJ has ranged from a low of $463.5177 (Apr 17, 2024) to a high of $476.9597 (Nov 12, 2025), with a median of $463.5177 per ML.
Are there cheaper alternatives to OTREXUP 17.5 MG/0.4 ML AUTOINJ?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, RASUVO 17.5 MG/0.35 ML AUTOINJ, is $409.9292 per ML — about 14% below OTREXUP 17.5 MG/0.4 ML AUTOINJ.
Who manufactures OTREXUP 17.5 MG/0.4 ML AUTOINJ?
OTREXUP 17.5 MG/0.4 ML AUTOINJ (NDC 54436001704) is labeled by Antares Pharma, Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification